|
Dr. Dennis Henner is a General Partner at MPM Capital. Dr. Henner joined MPM's San Francisco office in May 2001. Prior to joining MPM, Dr. Henner was at Genentech from 1981 to 2001. He was the Senior Vice President of Research at Genentech and a member of the Executive Committee, Product Review Committee, and Research Review Committee. During his tenure, he oversaw the development of numerous products that have been fundamental to the success of Genentech, including novel antibody products such as Herceptin. Dr. Henner is currently Director of Cellerant Therapeutics, Inc., Ceregene, Inc., Kalobios, Inc., Rinat Neuroscience Corporation, Synergia and Tercica, Inc (NASDAQ:TRCA). He received his Ph.D. from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation. Dr. Henner's scientific work focused on the expression of therapeutic proteins in bacterial hosts, and the development of recombinant antibody therapeutics. | 